BioSig CEO Kenneth L. Londoner to Present at the 33rd Annual Virtual ROTH Conference
March 09 2021 - 4:45PM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it will present at the 33rd Annual
Virtual ROTH Conference, being held on March 15-17, 2021. Kenneth
L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will
deliver a Company overview and provide updates on recent progress.
Mr. Londoner will also be available for investor meetings.
BioSig’s PURE EP™ System is an advanced signal acquisition and
processing platform that sets a new standard in electrophysiology.
The system provides essential diagnostic signals with high clinical
value in all types of cardiac ablations. More than 38 physicians
have completed over 580 patient cases with the PURE EP™ System
across 7 clinical sites.
Event: 33rd Annual Virtual ROTH Conference
Mr. Londoner’s presentation will be available on the Roth
Conference website beginning on March 10, 2021, and available for
90 days after that. To access the presentation on the conference
website, click here.
The same presentation will also be available on the Company’s
website.
The conference will feature presentations from public and
private companies across a variety of industry sectors. During
previous events, ROTH has hosted close to 550 participating
companies and attracted more than 5,000 attendees, including
institutional investors, analysts, family offices, and
high-net-worth investors.
About ROTH Capital Partners ROTH Capital
Partners, LLC (“ROTH”) is a relationship-driven investment bank
focused on serving emerging growth companies and their investors.
As a full-service investment bank, ROTH provides capital raising,
M&A advisory, analytical research, trading, market-making
services, and corporate access. Headquartered in Newport Beach, CA,
ROTH is privately held and employee-owned. For more information on
ROTH, please visit www.roth.com.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).The Company’s first product, PURE EP™
System is a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024